Sign in with Google. Opens in new tab
bullish
PYC-003 Shows Positive Preclinical Safety and Efficacy Data in Mice and NHPs
This morning, PYC released preclinical data in two species (mice, non-human primate) for its PYC-003 program in ADPKD (autosomal dominant polycystic kidney disease).
What is covered in the Full Insight:
- Introduction to PYC-003 and Preclinical Data Results
- Safety and Pharmacokinetics in Non-Human Primates
- Mechanism of Action and PC1 Protein Upregulation
- Next Steps: Human Trials and Regulatory Pathway
- Conclusion and Analyst's Investment Recommendation
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 16-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- ASX200 Index AdHoc Rebalance Preview: Potential Replacement for Spartan Resources (SPR AU)
- GMO Internet (4784) - Shares Appear Manipulated/Squeezed (Again), but ParentCo MUST SELL
- Merger Arb Mondays (14 Jul) - Shibaura, Topcon, Nissin, OneConnect, Insignia, PointsBet, ENN Energy
- BYD (1211 HK): Sales Volume Slowing Down in 2Q25, But Competitors Facing Cash Flow Stress
- Mandatory Cancellation of Existing Treasury Shares: A Historic Stock Market Event in the Making
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- PYC-003 Shows Positive Preclinical Safety and Efficacy Data in Mice and NHPs02 Dec 2024
x